/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2021-11-16 19:12:282021-12-10 13:02:09Synthekine Announces $107.5 Million Oversubscribed Series B Financing to Support Lead Programs to Clinical Proof of Concept, Advance Preclinical Programs and Platform
/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2021-11-16 19:08:272021-12-10 13:02:38Synthekine Expands Board of Directors, Management Team and Scientific Advisory Board with New Key Appointments
/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2021-11-16 18:11:242021-12-10 13:04:37Synthekine Presents Data at American Society of Hematology Annual Meeting Showing Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19 CAR-T
/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2021-11-16 18:07:262021-12-10 13:04:57Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases
